Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (14394)
All Articles published online
|
Publishing Process of This Article
|
Sep 14, 2013 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | D’Incà R, Paccagnella M, Cardin R, Pathak S, Baldo V, Giron MC, Sturniolo GC. 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis. World J Gastroenterol 2013; 19(34): 5665-5670 [PMID: 24039359 DOI: 10.3748/wjg.v19.i34.5665] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v19/i34/5665.htm |
| Number | Citing Articles |
| 1 |
Ajit Sood, Vineet Ahuja, Vandana Midha, Saroj Kant Sinha, C. Ganesh Pai, Saurabh Kedia, Varun Mehta, Sawan Bopanna, Philip Abraham, Rupa Banerjee, Shobna Bhatia, Karmabir Chakravartty, Sunil Dadhich, Devendra Desai, Manisha Dwivedi, Bhabhadev Goswami, Kirandeep Kaur, Rajeev Khosla, Ajay Kumar, Ramit Mahajan, S. P. Misra, Kiran Peddi, Shivaram Prasad Singh, Arshdeep Singh. Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease. Intestinal Research 2020; 18(4): 355 doi: 10.5217/ir.2019.09176
|
| 2 |
Pompilia Ispas-Szabo, Mihaela Maria Friciu, Phuong Nguyen, Yves Dumoulin, Mircea Alexandru Mateescu. Novel self-assembled mesalamine–sucralfate complexes: preparation, characterization, and formulation aspects. Drug Development and Industrial Pharmacy 2016; 42(7): 1183 doi: 10.3109/03639045.2015.1118493
|
| 3 |
Tomohiro Fukuda, Makoto Naganuma, Kaoru Takabayashi, Yuya Hagihara, Shun Tanemoto, Ena Nomura, Yusuke Yoshimatsu, Shinya Sugimoto, Kosaku Nanki, Shinta Mizuno, Yohei Mikami, Kayoko Fukuhara, Tomohisa Sujino, Makoto Mutaguchi, Nagamu Inoue, Haruhiko Ogata, Yasushi Iwao, Takayuki Abe, Takanori Kanai. Mucosal concentrations of N‐acetyl‐5‐aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine. Journal of Gastroenterology and Hepatology 2020; 35(11): 1878 doi: 10.1111/jgh.15059
|
| 4 |
UEG Week 2018 Poster Presentations. United European Gastroenterology Journal 2018; 6(S8) doi: 10.1177/2050640618792819
|
| 5 |
Maartje M. van de Meeberg, Elwin R. Verheij, Herma H. Fidder, Gerd Bouma, Alwin D.R. Huitema, Bas Oldenburg. Potential of Mesalazine Therapeutic Drug Monitoring by Measuring Fecal Excretion in Patients With Ulcerative Colitis. Therapeutic Drug Monitoring 2023; 45(5): 668 doi: 10.1097/FTD.0000000000001084
|
| 6 |
Hiromu Morikubo, Taku Kobayashi, Ryo Ozaki, Shinji Okabayashi, Satoshi Kuronuma, Osamu Takeuchi, Tenyo Shiba, Hiroki Kiyohara, Mao Matsubayashi, Shintaro Sagami, Masaru Nakano, Osamu Ikezaki, Tadakazu Hisamatsu, Yoichi Tanaka, Toshifumi Hibi. Differential effects of mesalazine formulations on thiopurine metabolism through thiopurine S‐methyltransferase inhibition. Journal of Gastroenterology and Hepatology 2021; 36(8): 2116 doi: 10.1111/jgh.15411
|
| 7 |
Alvaro Goyanes, Grace B. Hatton, Hamid A. Merchant, Abdul W. Basit. Gastrointestinal release behaviour of modified-release drug products: Dynamic dissolution testing of mesalazine formulations. International Journal of Pharmaceutics 2015; 484(1-2): 103 doi: 10.1016/j.ijpharm.2015.02.051
|
| 8 |
Niels Vande Casteele, Abhijeet Jakate, Brian McNamee, William J. Sandborn. Similar pharmacokinetics of three dosing regimens comprising two oral delayed‐release mesalamine formulations in healthy adult volunteers: Randomised, open‐label, parallel‐group study. British Journal of Clinical Pharmacology 2021; 87(3): 1141 doi: 10.1111/bcp.14479
|
| 9 |
Helmut Deissler, Heinrich Krammer, Anton Gillessen. pH‑dependent vs. constant release of mesalazine in the treatment of ulcerative colitis: Do drug delivery concepts determine therapeutic efficacy? (Review). Biomedical Reports 2021; 15(5) doi: 10.3892/br.2021.1472
|
| 10 |
Solmaz Zakhireh, Mehrdad Mahkam, Mehdi Yadollahi, Saeed Jafarirad. Investigation of pH-sensitive galactopyranoside glycol hydrogels as effective vehicles for oral drug delivery. Journal of Polymer Research 2014; 21(4) doi: 10.1007/s10965-014-0398-3
|
| 11 |
Chen Diling, Yang Xin, Zheng Chaoqun, Yang Jian, Tang Xiaocui, Chen Jun, Shuai Ou, Xie Yizhen. Extracts from Hericium erinaceus relieve inflammatory bowel disease by regulating immunity and gut microbiota. Oncotarget 2017; 8(49): 85838 doi: 10.18632/oncotarget.20689
|
| 12 |
Reidar Fossmark, Maya Olaisen, Tom Christian Martinsen, Hans Olav Melberg. Factors associated with the persistence of oral 5-aminosalicylic acid monotherapy in ulcerative colitis: a nationwide Norwegian cohort study. Therapeutic Advances in Gastroenterology 2021; 14: 175628482110217 doi: 10.1177/17562848211021760
|
| 13 |
Soleiman B. Kashkooli, Mehrdad Rouhani, Fred Saibil. Ultra-high dose of mesalamine to treat steroid-dependent ulcerative colitis. Journal of Crohn's and Colitis 2014; 8(12): 1745 doi: 10.1016/j.crohns.2014.08.007
|
| 14 |
O. V. Knyazev, A. V. Kagramanova, A. A. Lishchinskaya. Effectiveness of treatment of moderate ulcerative colitis with prolonged mesalazine in real clinical practice. Meditsinskiy sovet = Medical Council 2021; (15): 144 doi: 10.21518/2079-701X-2021-15-144-151
|
| 15 |
Adeyinka Abinusawa, Srini Tenjarla. Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels. Advances in Therapy 2015; 32(5): 477 doi: 10.1007/s12325-015-0206-4
|
| 16 |
O. V. Knyazev, A. V. Kagramanova, A. A. Lishchinskaya, A. I. Parfenov. The effectiveness of mesalazine therapy of ulcerative colitis of moderate severity in real clinical practice. Medical Council 2019; (14): 80 doi: 10.21518/2079-701X-2019-14-80-86
|
| 17 |
O. V. Knyazev, A. V. Kagramanova, A. A. Lishchinskaya, A. F. Babaian, T. V. Shkurko, B. A. Nanaeva, I. A. Li. Comparative evaluation of the effectiveness of monotherapy of ulcerative colitis with mesalazine MMX and combination therapy with non-prolonged mesalazines with rectal forms. Meditsinskiy sovet = Medical Council 2022; (14): 96 doi: 10.21518/2079-701X-2022-16-14-96-106
|
| 18 |
Oleg V. Knyazev, Аnna V. Kagramanova, Alexey V. Veselov, Tatyana V. Skurko. Effectiveness of treatment moderate ulcerative colitis with prolonged-release ethylcellulose-coated mesalazine in real clinical practice in Moscow. City Healthcare 2021; 2(2): 65 doi: 10.47619/2713-2617.zm.2021.v2i2;65-74
|
| 19 |
Lee Ann Hodges. Multiparticulate Drug Delivery. Advances in Delivery Science and Technology 2017; : 359 doi: 10.1007/978-1-4939-7012-4_14
|
| 20 |
Aurelio Romero-Castro, Mara Gutiérrez-Sánchez, José Correa-Basurto, Martha Cecilia Rosales Hernández, Itzia Irene Padilla Martínez, Jessica Elena Mendieta-Wejebe, Mária A. Deli. Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity. PLOS ONE 2016; 11(7): e0159889 doi: 10.1371/journal.pone.0159889
|
| 21 |
Masaki Kato, Kohei Sugiyama, Maki Miyakawa, Masanao Nasuno, Hiroki Tanaka, Satoshi Motoya. Efficacy of Multi Matrix System Mesalazine for the Induction of Remission in Patients with Ulcerative Colitis who Insufficiently Respond toother Mesalazine Formulations: A Japanese Single-center Study. Nippon Daicho Komonbyo Gakkai Zasshi 2021; 74(6): 357 doi: 10.3862/jcoloproctology.74.357
|
| 22 |
Ilaria Marsilio, Valentina Caputi, Eva Latorre, Silvia Cerantola, Andrea Paquola, Ana I. Alcalde, José E. Mesonero, Siobhain M. O'Mahony, Antonella Bertazzo, Cristina Giaroni, Maria Cecilia Giron. Oxidized phospholipids affect small intestine neuromuscular transmission and serotonergic pathways in juvenile mice. Neurogastroenterology & Motility 2021; 33(4) doi: 10.1111/nmo.14036
|
| 23 |
Satohiro Masuda, Yuki Yamamoto. Drug delivery system in treatment against inflammatory bowel disease: present and future. Drug Delivery System 2018; 33(5): 397 doi: 10.2745/dds.33.397
|
| 24 |
Kousaku Kawashima, Shunji Ishihara, Takafumi Yuki, Koji Onishi, Yoshinori Kushiyama, Hirofumi Fujishiro, Youichi Miyaoka, Mika Yuki, Yoshinori Komazawa, Takashi Tanimura, Hiroki Sonoyama, Yasumasa Tada, Ryusaku Kusunoki, Akihiko Oka, Nobuhiko Fukuba, Naoki Oshima, Ichiro Moriyama, Yoshikazu Kinoshita. Therapeutic Efficacy of pH-Dependent Release Formulation of Mesalazine on Active Ulcerative Colitis Resistant to Time-Dependent Release Formulation: Analysis of Fecal Calprotectin Concentration. BioMed Research International 2014; 2014: 1 doi: 10.1155/2014/342751
|
| 25 |
Dorota Haznar-Garbacz, Grzegorz Garbacz, Werner Weitschies. Development of oral foams for topical treatment of inflammatory bowel disease. Journal of Drug Delivery Science and Technology 2019; 50: 287 doi: 10.1016/j.jddst.2019.01.022
|
| 26 |
Maya Olaisen, Olav Spigset, Arnar Flatberg, Atle van Beelen Granlund, Wenche Rødseth Brede, Grethe Albrektsen, Elin Synnøve Røyset, Bodil Gilde, Arne Kristian Sandvik, Tom Christian Martinsen, Reidar Fossmark. Mucosal 5‐aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis. Alimentary Pharmacology & Therapeutics 2019; 49(10): 1301 doi: 10.1111/apt.15227
|
| 27 |
Maricelma da Silva Soares de Souza, Sandra Maria Barbalho, Ricardo de Alvares Goulart, Antonely de Cássio Alves de Carvalho. The Current and Future Role of Drugs and Probiotics in the Management of Inflammatory Bowel Disease. Journal of Biosciences and Medicines 2015; 3(08): 76 doi: 10.4236/jbm.2015.38008
|
| 28 |
Yuki Yamamoto, Satohiro Masuda, Hiroshi Nakase, Minoru Matsuura, Shihoko Maruyama, Tadakazu Hisamatsu, Yasuo Suzuki, Kazuo Matsubara. Influence of Pharmaceutical Formulation on the Mucosal Concentration of 5-Aminosalicylic Acid and <i>N</i>-Acetylmesalamine in Japanese Patients with Ulcerative Colitis. Biological and Pharmaceutical Bulletin 2019; 42(1): 81 doi: 10.1248/bpb.b18-00561
|
| 29 |
Takayuki Yoshida, Hiroyuki Kojima. Oral Drug Delivery Systems Applied to Launched Products: Value for the Patients and Industrial Considerations. Molecular Pharmaceutics 2023; 20(11): 5312 doi: 10.1021/acs.molpharmaceut.3c00482
|
| 30 |
Makoto Naganuma. Solving the questions regarding 5-aminosalitylate formulation in the treatment of ulcerative colitis. Journal of Gastroenterology 2020; 55(11): 1013 doi: 10.1007/s00535-020-01713-8
|
| 31 |
Jingjing Li, Suiyuan Ren, Meng Li, Jingai Bi, Guang Yang, Erguang Li. Paeoniflorin protects against dextran sulfate sodium (DSS)-induced colitis in mice through inhibition of inflammation and eosinophil infiltration. International Immunopharmacology 2021; 97: 107667 doi: 10.1016/j.intimp.2021.107667
|
| 32 |
Silvia Cerantola, Valentina Caputi, Ilaria Marsilio, Manuela Ridolfi, Sofia Faggin, Michela Bistoletti, Cristina Giaroni, Maria Cecilia Giron. Involvement of Enteric Glia in Small Intestine Neuromuscular Dysfunction of Toll-Like Receptor 4-Deficient Mice. Cells 2020; 9(4): 838 doi: 10.3390/cells9040838
|
| 33 |
E. R. Donсova, O. V. Remizov, N. V. Novoselya. Pancreatitis: common but forgotten causes. Medical Herald of the South of Russia 2021; 12(2): 96 doi: 10.21886/2219-8075-2021-12-2-96-99
|